Shares in Glaukos (NYSE:GKOS) have fallen today after the ophthalmic medical tech company posted first quarter earnings that saw profits swing to losses, despite topping The Street’s expectations. The San Clemente, Calif.-based company posted losses of $2.7 million, or 8¢ per share, on sales of $40.1 million for the three months ended March 31, seeing an […]
Report: J&J’s Cerenovus to discontinue Codman liver cancer pump
Johnson & Johnson‘s (NYSE:JNJ) Cerenovus is discontinuing production of its Codman pumps designed to deliver targeted chemotherapy to the liver for patients with liver cancer, according to a New York Times report. The devices are designed to be implanted in the abdomen to deliver chemotherapy directly to the liver to treat cancer that has spread […]
Theravance Biopharma touts expanded FDA nod for GSK’s Trelegy Ellipta inhaler
Theravance Biopharma‘s (NSDQ:TBPH) said today that the FDA granted expanded indications for GlaxoSmithKline‘s (NYSE:GSK) Trelegy Ellipta inhaler, now approved for use to treat a broader population of chronic obstructive pulmonary disease patients. With the expansion, the inhaler is now cleared for COPD patients with airflow limitations and for those who have experienced an acute worsening of […]
Shire accepts $64B takeover bid from Takeda
Shire (NSDQ:SHPG) said late yesterday it agreed to Takeda Pharmaceutical‘s (TYO:4502) reworked acquisition bid, now worth approximately $64.2 billion (GBP £46 billion). The takeover offer will now go to Shire’s shareholders for approval, having received backing from Dublin, Ireland-based Shire’s board of directors, according to a press release. In the deal, Takeda will offer approximately 0.839 […]
EryDel raises $32m (€27m) for red blood cell drug delivery tech
Italian red blood cell drug delivery tech developer EryDel has raised $32 million (EU €26.5 million) in a new round of financing. The round was led by Sofinnova Partners and joined by existing shareholder Genextra SpA and Innogest SGR, according to a Sofinnova release. “We are thrilled to welcome Sofinnova Partners as our lead investor. […]
Valeritas prices $24m offering
Valeritas (NSDQ:VLRX) today announced a new $24 million offering. In the offering, the Bridgewater, N.J.-based company will look to float approximately 13.7 million shares of common stock at $1.75 per share. The offering will also include a 30-day underwriter’s option for an additional 2.1 million shares at the same price. Before deducting underwriter’s discounts and commissions, […]
Report: Takeda raises $60B offer for Shire, nears prelim acquisition agreement
Takeda Pharmaceutical (TYO:4502) has sweetened its approximately $60 billion bid for Shire (NSDQ:SHPG) and is approaching a preliminary agreement for acquisition, according to a new report from Bloomberg. The deal could come to a head as early as today, according to the report, as both companies have been working on a tentative agreement and price for the […]
Livongo Health acquires weight-management, disease-prevention dev Retrofit
Livongo Health said yesterday it acquired weight-management and disease-prevention program developer Retrofit for an undisclosed amount. With the acquisition, Mountain View, Calif.-based Livongo Health said it will make Retrofit’s Diabetes Prevention program available as Livongo DPP, powered by Retrofit. Livongo said the acquisition acts as a compliment to its Livongo for Diabetes and Livongo for Hypertension […]
Report: Amazon abandons drug distribution and supply plans
Amazon‘s (NSDQ:AMZN) Business division has dropped plans to sell and distribute pharmaceutical products to hospitals, according to a new report from CNBC. The shift comes due to the online mega-retailer being unable to convince large hospital groups to change their purchasing process and break existing deals and relationships with distributors, according to the report. The […]
House passes “right to try” bill allowing use of experimental drugs for terminally ill patients
The US House of Representatives yesterday passed a bill aiming to expand the “right to try” experimental drugs, sending the bill, which is backed by President Trump, to the Senate. The bill would allow terminally ill patients access to investigational drugs drugs that haven’t been approved by the FDA, according to a report from The […]
